← ACADIA PHARMACEUTICALS INC
| Annual Trend | FY 2016 | FY 2017 | FY 2018 | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $17.3m | $124.9m | $223.8m | $339.1m | $441.8m | $484.1m | $517.2m | $726.4m | $957.8m | $1.1b | |
| Cost of Revenue | $3.1m | $9.1m | $205.5m | $11.3m | $10.2m | $10.8m | $10.2m | $41.6m | $81.8m | $89.0m | |
| Gross Profit (derived) | $14.3m | $115.8m | $211.4m | $327.7m | $431.5m | $473.3m | $507.1m | $684.8m | $876.0m | $982.5m | |
| Operating expenses: | |||||||||||
| Operating Income (Loss) | ($272.8m) | ($292.4m) | ($247.4m) | ($246.5m) | ($286.6m) | ($170.4m) | ($223.6m) | ($73.4m) | $230.8m | $104.8m | |
| Additional Financial Items | |||||||||||
| Amortization of Intangible Assets | $985k | $1.5m | $1.5m | $1.5m | $1.5m | $1.1m | $0 | $4.1m | $15.0m | $10.9m | |
| Gain (Loss) on Investments | — | — | ($1.8m) | $997k | ($997k) | $2.3m | $3.5m | $5.1m | $0 | $0 | |
| Income (Loss) from Continuing Operations before Income Taxes, Domestic | ($18.4m) | ($45.2m) | ($78.1m) | ($123.4m) | ($238.9m) | ($138.9m) | ($233.2m) | ($100.2m) | $95.8m | $72.2m | |
| Income (Loss) from Equity Method Investments | ($270.1m) | ($288.3m) | ($243.9m) | ($234.4m) | ($281.0m) | ($167.5m) | ($213.4m) | ($51.0m) | $258.1m | $138.9m | |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest | ($270.1m) | ($288.3m) | ($243.9m) | ($234.4m) | ($281.0m) | ($167.5m) | ($213.4m) | ($51.0m) | $258.1m | $138.9m | |
| Net Income (Loss) Attributable to Parent | ($271.4m) | ($289.4m) | ($245.2m) | ($235.3m) | ($281.6m) | ($167.9m) | ($216.0m) | ($61.3m) | $226.5m | $391.0m | |
| Net Income (Loss) Available to Common Stockholders, Basic | — | — | — | — | — | — | — | — | $226.5m | $391.0m | |
| Earnings Per Share, Basic | — | — | — | — | ($1.79) | ($1.05) | ($1.34) | ($0.37) | $1.37 | $2.32 | |
| Earnings Per Share, Diluted | ($2.34) | ($2.36) | ($1.94) | ($1.60) | ($1.79) | ($1.05) | ($1.34) | ($0.37) | $1.36 | $2.30 | |
| Weighted Average Number of Shares Outstanding, Basic | — | — | — | — | 157k | 160k | 162k | 164k | 165.7m | 168.4m | |
| Weighted Average Number of Shares Outstanding, Diluted | — | — | — | — | 157k | 160k | 162k | 164k | 166.4m | 169.9m | |
| Research and Development Expense | $99.3m | $149.2m | $187.2m | $240.4m | $319.1m | $239.4m | $361.6m | $351.6m | $303.2m | $328.8m | |
| Selling, General and Administrative Expense | $186.5m | $255.1m | $265.8m | $325.6m | $388.7m | $396.0m | $369.1m | $406.6m | $488.4m | $548.9m | |
| Other Nonoperating Income (Expense) | — | — | — | $997k | ($997k) | ($2.3m) | $3.5m | $5.1m | $1.8m | $2.4m | |
| Costs and Expenses | $290.1m | $417.3m | $471.3m | $585.6m | $728.3m | $654.6m | $740.8m | $799.8m | $727.0m | $966.7m | |
| Current Income Tax Expense (Benefit) | $1.3m | $1.1m | $1.3m | $876k | $611k | $351k | $2.5m | $10.2m | $31.6m | ($1.8m) | |
| Share-based Payment Arrangement, Expensed and Capitalized, Amount | — | — | — | — | — | $600k | $300k | $3.6m | — | — | |
| Income Tax Expense (Benefit) | $1.3m | $1.1m | $1.3m | $876k | $611k | $351k | $2.5m | $10.2m | $31.6m | ($252.1m) | |
| Interest Income (Expense), Nonoperating, Net | $2.8m | $4.1m | $5.3m | $11.2m | $6.6m | $591k | $6.6m | $17.2m | $25.5m | $31.7m |
Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.